Pub. Date : 1986 Jul
PMID : 3014113
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Uptake of N-[1 (S)-carboxy-(4-OH-3-125I-phenyl)ethyl]-L-Ala-L-Pro, an inhibitor of angiotensin-converting enzyme by rabbit lungs in situ. | n-[1 (s)-carboxy-(4-oh-3-125i-phenyl)ethyl]-l-ala-l-pro | angiotensin-converting enzyme | Oryctolagus cuniculus |
| 2 | In 13 of 21 lungs used, a synthetic substrate for ACE, [3H]benzoyl-phenylalanyl-alanyl-proline (BPAP), was added to the bolus and appearance of its hydrolysis product, [3H]benzoyl-Phe, measured in effluent samples. | bpap | angiotensin-converting enzyme | Oryctolagus cuniculus |
| 3 | In 13 of 21 lungs used, a synthetic substrate for ACE, [3H]benzoyl-phenylalanyl-alanyl-proline (BPAP), was added to the bolus and appearance of its hydrolysis product, [3H]benzoyl-Phe, measured in effluent samples. | [3h]benzoyl-phe | angiotensin-converting enzyme | Oryctolagus cuniculus |
| 4 | Coadministration of the ACE inhibitor, captopril (3, 6, 8 and 28 nmol), also caused dose-dependent, reversible depression of both E(CPAP) and M(BPAP). | Captopril | angiotensin-converting enzyme | Oryctolagus cuniculus |
| 5 | Coadministration of the ACE inhibitor, captopril (3, 6, 8 and 28 nmol), also caused dose-dependent, reversible depression of both E(CPAP) and M(BPAP). | cpap | angiotensin-converting enzyme | Oryctolagus cuniculus |
| 6 | Coadministration of the ACE inhibitor, captopril (3, 6, 8 and 28 nmol), also caused dose-dependent, reversible depression of both E(CPAP) and M(BPAP). | bpap | angiotensin-converting enzyme | Oryctolagus cuniculus |
| 7 | Inasmuch as CPAP inhibits ACE activity (as reflected by BPAP metabolism) and CPAP uptake is inhibited by captopril (which also inhibits BPAP hydrolysis), it appears that a large portion of this saturable process probably reflects binding to vascular ACE. | cpap | angiotensin-converting enzyme | Oryctolagus cuniculus |